血清诱骗受体 3 γ-干扰素和抗环瓜氨酸肽抗体在风湿性 关节炎患者中的表达及意义

doi:10.3969/j.issn.1006-6233.2019.04.045

摘要
图/表
参考文献
相关文章 (1)

全文: PDF (1607 KB) HTML (0 KB)
输出: BibTeX | EndNote (RIS)

摘要目的:探讨血清诱骗受体 3、γ-干扰素、抗环瓜氨酸肽抗体在风湿性关节炎患者中的表达及意义。方法:选择2017年2月至2017年12月我院接诊的70例风湿性关节炎患者作为观察组,并选择我院同期接受健康体检的65例健康受试者作为对照组,采集所有受试者入组后第2天清晨空腹静脉血,检测血清诱骗受体 3、γ-干扰素、抗环瓜氨酸肽抗体的表达,分析血清诱骗受体 3、γ-干扰素、抗环瓜氨酸肽抗体在风湿性关节炎患者中的变化及意义。结果:观察组血清诱骗受体 3、γ-干扰素、抗环瓜氨酸肽抗体分别为(4631.05±3180.24)pg/mL、(1341.23±482.94)pg/mL、(86.51±6.38)U/mL,对照组分别为(481.53±150.07)pg/mL、(248.79±62.63)pg/mL、(45.41±8.35)U/mL,差异具有统计学意义(P<0.05);通过Pearson相关性分析显示,血清诱骗受体 3、γ-干扰素和抗环瓜氨酸肽抗体水平呈正相关(r=0.658、0.744,P<0.05)。结论:风湿性关节炎患者中血清诱骗受体 3、γ-干扰素、抗环瓜氨酸肽抗体均明显升高,且血清诱骗受体 3、γ-干扰素和抗环瓜氨酸肽抗体水平均呈正相关,可辅助诊断风湿性关节炎。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邓秋萍
	莫巧璇
	简少珍
	张间霞

关键词 ：血清诱骗受体3, γ-干扰素, 抗环瓜氨酸肽抗体, 风湿性关节炎

Abstract：Objective: To investigate the expression and significance of serum decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis. Methods: Seventy patients with rheumatoid arthritis admitted to our hospital from February 2017 to December 2017 were selected as observation group, and 65 healthy subjects who received health examination in our hospital during the same period were selected as control group. Fasting venous blood was collected from all subjects on the morning of the 2nd day after admission. The expression of serum decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibody was detected. The changes and significance of serum decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis were analyzed. Results: The serum levels of decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies in the observation group were (4631.05 (+3180.24) pg/mL, (1341.23 (+482.94) pg/mL and (86.51 (+6.38) U/mL, respectively, while those in the control group were (481.53 (+150.07) pg/mL, (248.79 (+62.63) pg/mL and (45.41 (+8.35) U/mL, respectively, with statistical differences (P<0.05); Pearson correlation analysis showed that the serum levels of decoy receptor 3, interferon and anti-cyclic Cit Deception receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibody levels were positively correlated (r = 0.658, 0.744, P<0.05). Conclusion: The serum levels of decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis were significantly increased, and the serum levels of decoy receptor 3, interferon-gamma and anti-cyclic citrullinated peptide antibodies were positively correlated, which could assist in the diagnosis of rheumatoid arthritis.

Key words： Serum decoys receptor 3 Gamma interferon Anti-cyclic citrullinated peptide antibody Rheumatoid arthritis

基金资助:广东省佛山市卫生和计生局科研课题,(编号:A20190096)

引用本文:

邓秋萍, 莫巧璇, 简少珍, 张间霞. 血清诱骗受体 3 γ-干扰素和抗环瓜氨酸肽抗体在风湿性关节炎患者中的表达及意义[J]. 河北医学, 2019, 25(4): 699-701.
DENG Qiuping, MO Qiaoxuan, JIAN Shaozhen, et al. Expression and Significance of Serum Decoy Receptor 3, Interferon-gamma and Anti-cyclic Citrullinated Peptide Antibodies in Patients with Rheumatic Arthritis. HeBei Med, 2019, 25(4): 699-701.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2019.04.045 或 http://www.hbyxzzs.cn/CN/Y2019/V25/I4/699

[1] Taal E, Rasker J J, Wiegman O. Group education for rheumatoid arthritis patients.[J]. Seminars in Arthritis & Rheumatism, 2017, 26(6):805~816.
[2] Shahrara S, Pickens S R, Dorfleutner A, et al. IL-17 induces monocyte migration in rheumatoid arthritis[J]. Journal of Immunology, 2016, 182(6):3884~3891.
[3] Singh J A, Saag K G, Jr B S, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis.[J]. Arthritis Care Res, 2016, 68(1):1~25.
[4] Burmester G R, Rigby W F, Vollenhoven R F V, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial[J]. Annals of the Rheumatic Diseases, 2016, 75(6):1081~1091.
[5] Ferro F, Elefante E, Luciano N, et al. One year in review 2017: novelties in the treatment of rheumatoid arthritis.[J]. Clinical & Experimental Rheumatology, 2017, 35(5):721~734.
[6] Kobayashi T, Ito S, Kuroda T, et al. The interleukin‐1 and fcγ receptor gene polymorphisms in japanese patients with rheumatoid arthritis and periodontitis[J]. Journal of Periodontology, 2017, 78(12):2311~2318.
[7] Catrina A I, Joshua V, Klareskog L, et al. Mechanisms involved in triggering rheumatoid arthritis[J]. Immunological Reviews, 2016, 269(1):162~174.
[8] Barile A, Arrigoni F, Bruno F, et al. Computed tomography and MR imaging in rheumatoid arthritis.[J]. Radiol Clin North Am, 2017, 55(5):997~1007.
[9] Taylor P C, Keystone E C, Van d H D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis.[J]. N Engl Med, 2017, 376(7):652~662.
[10] Cramp F, Hewlett S, Almeida C, et al. Non-pharmacological interventions for fatigue in rheumatoid arthritis.[J]. Cochrane Database Syst Rev, 2016, 8(8):997~1005.
[11] Solomon J J, Chung J H, Cosgrove G P, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease[J]. European Respiratory Journal, 2016, 47(2):588~596.
[12] Mercan R, Bitik B, Tufan A, et al. The association between neutrophil/Lymphocyte ratio and disease activity in rheumatoid arthritis and ankylosing spondylitis.[J]. Journal of Clinical Laboratory Analysis, 2016, 30(5):597~601.